Abstract
The potential utility of tumour-selective 5-fluorouracil treatment using attenuated Salmonella serovar typhimurium recombinant for cytosine deaminase (TAPET-CD) has been documented in experimental settings. The present data demonstrate that in vivo (19)F-magnetic resonance spectroscopy measurements allow the outcome prediction of this prokaryotic-based therapy, demonstrating the necessity of non-invasive real-time imaging techniques for treatment monitoring.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / analysis
-
Antineoplastic Agents / metabolism*
-
Antineoplastic Agents / therapeutic use
-
Blotting, Western
-
Chromatography, Thin Layer
-
Cytosine Deaminase / genetics
-
Cytosine Deaminase / therapeutic use*
-
Female
-
Flucytosine / analysis
-
Flucytosine / metabolism*
-
Flucytosine / therapeutic use
-
Fluorouracil / analysis
-
Fluorouracil / metabolism*
-
Fluorouracil / therapeutic use
-
Genetic Therapy / methods*
-
Genetic Vectors
-
Humans
-
Magnetic Resonance Spectroscopy
-
Mice
-
Neoplasms, Experimental / therapy*
-
Prodrugs / analysis
-
Prodrugs / metabolism
-
Prodrugs / therapeutic use
-
Salmonella typhimurium / genetics
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Prodrugs
-
Flucytosine
-
Cytosine Deaminase
-
Fluorouracil